Allucent Launches IGNITE™ Site Network to Accelerate Clinical Trial Execution for Small and Mid-Sized Biopharma
核心洞察
Allucent (搜索) announced the launch of IGNITE™, a performance-based global network encompassing more than 250 pre-qualified clinical research sites across six therapeutic areas.
The network provides accelerated feasibility assessments within 72 hours and commits to site activation within 60 days of final protocol in North America.
IGNITE is built on long-term strategic partnerships rather than study-by-study site selection, offering sponsors access to patient populations representing over 50 million individuals.
Allucent (搜索), a global specialty contract research organization (CRO) purpose-built for small and mid-sized biopharma, today announced the launch of its Integrated Global Network for Innovative Trial Execution (IGNITE™). The performance-based global network, encompassing more than 250 pre-qualified clinical research sites, is designed to improve study predictability, accelerate site activation and patient recruitment, and reduce development risk for sponsors navigating increasingly complex clinical programs.
The IGNITE network connects sponsors with high-performing research sites aligned with Allucent (搜索)'s therapeutic Centers of Expertise (ACEs) across six key areas: oncology and hematology, neuroscience, cardiometabolic diseases, immunology and inflammation, infectious diseases, and rare diseases.
A Differentiated Model Built on Strategic Partnerships
Unlike traditional site networks that rely on study-by-study site selection, IGNITE is built around long-term strategic partnerships and mutual accountability between sponsors, CRO teams, and participating sites. Site partners benefit from earlier study engagement, streamlined processes, and access to trials aligned with their expertise. In turn, sponsors gain access to experienced investigators and patient populations representing more than 50 million individuals across therapeutic areas relevant to their studies.
"Today's development environment demands more than access to sites, it requires confidence in execution," said Patrick Phillips, chief operating officer of Allucent (搜索). "IGNITE brings together proven site partners, therapeutic expertise, and clear operational commitments to help sponsors move from protocol to patient enrollment faster and with greater predictability. It's a differentiated approach that creates stronger alignment across sponsors, sites, and patients, helping reduce execution risk and improve trial predictability."
Defined Execution Commitments
IGNITE provides sponsors with accelerated feasibility assessments, including responses within 72 hours, and access to pre-qualified sites committed to defined timelines. These commitments include site activation within 60 days of final protocol in North America and within three to four weeks following regulatory approvals outside North America, enabling sponsors to move efficiently from protocol approval to patient screening.
The network supports study execution from the first patient in through the last patient enrolled, helping sponsors reduce variability and anticipate challenges earlier to maintain trial momentum.
"Strong enrollment outcomes start with selecting the right sites and engaging them early," said Almenia Garvey, senior director of global feasibility, site and patient engagement at Allucent (搜索). "Through IGNITE, we're building deeper partnerships with sites that share our commitment to quality, responsiveness, and performance. That means sponsors can move studies forward with greater confidence, reaching milestones faster and keeping programs on track when it matters most."
Strengthening the Specialty CRO Model
The launch of IGNITE further strengthens Allucent (搜索)'s specialty CRO model, bringing together therapeutic expertise, technology and AI, site strategy, and global trial execution to help emerging biopharma companies navigate increasingly complex development programs. Allucent has conducted more than 1,090 studies across over 75 countries involving more than 155,000 patients, combining global reach with deep expertise across complex and rare indications.